Drugs / Dimolegin
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05181241 | Jan → Dec 2017 | — | PharmaDiall Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05189002 | May 2019 → Aug 2021 | venous thromboembolism | PharmaDiall Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07124819 | Jul 2024 → Jan 2025 | osteoarthritis, hip, osteoarthritis, knee, venous thromboembolism | Avexima Diol LLC | Completed | No outcome recorded |
| Phase 3 | NCT05185804 | Feb → Aug 2021 | COVID-19, venous thromboembolism | PharmaDiall Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dimolegin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05185804 ↗ |
| Action | Inhibit | “Direct Factor Xa Inhibitor Dimolegin (DD217)” NCT05189002 ↗ |
| Route | Oral | “Cohort 7 volunteers continued to take 60 mg of the study drug orally once and completed the study.” NCT05181241 ↗ |